Effect of Ticagrelor on TIMI, TMPG, CTFC, MACE and Cardiac Function in Patients with STEMI Undergoing PCI Treatment

  • Yingxiao Li
Keywords: STEMI, PCI, Ticagrelor, TIMI, TMPG, CTFC, MACE, Cardiac Function


To investigate the effect of ticagrelor on thrombolysis risk score (TIMI), TIMI myocardial perfusion score
(TMPG), TIMI frame number (CTFC), major adverse cardiovascular events (MACE) and cardiac function in
patients with acute ST elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention
(PCI) treatment. Methods: This study included 124 STEMI patients who were treated with PCI in our hospital
from June 2017 to December 2018. They were randomly divided into two groups: Xinweining group and
ticagrelor group, 62 cases in each group. The patients in Xinweining group were given intravenous injection of
Xinweining during the operation; the load was 0.4 μ / kg ꞏ min-1, and the maintenance dose was 0.1 μ / kg ꞏ min-1.
The intravenous drip continued for 36 hours after the operation. The patients in ticagrelor group were given
300mg aspirin enteric-coated tablets and 180mg ticagrelor for 3 times /d, 30 minutes before the operation, and
100mg aspirin enteric-coated tablets and 90mg ticagrelor for 2 times / d after the operation. The changes of
implantation time, average length of stent, average diameter of stent, TIMI, TMPG, CTFC, MACE, incidence of
adverse reactions, myocardial enzyme spectrum index and cardiac function [maximum mitral flow rate in early
diastole phase/ maximum mitral flow rate in atrial systole period (E/A value), left ventricular end diastolic
dimension (LVEDD), left ventricular ejection fraction (LVEF)] were compared before and after the operation.
There was no significant difference in implantation time, average stent length and average stent diameter
between ticagrelor group and Xinweining group (P > 0.05). Compared with the Xinweining group, the specific
value of TIMI-3 and TMPG-3 in ticagrelor group rose significantly, and the incidence of CTFC and no reflow /
slow flow significantly lowered (P < 0.05). Compared with the incidence of Xinweining group (40.32%), the
incidence of MACE in ticagrelor group (9.68%) significantly decreased (P < 0.05). Compared with
pre-treatment, the E/A, LVEDD and LVEF of the two groups significantly increased after the treatment;
compared with the Xinweining group, the E/A, LVEDD and LVEF of the ticagrelor group significantly rose (P
< 0.05). After the treatment, compared with Xinweining group, the ST segment depression in ticagrelor group
significantly rose (P < 0.05). Compared with 14.52% in Xinweining group, 4.84% in ticagrelor group was
significantly lower (P < 0.05). Ticagrelor can significantly alleviate myocardial perfusion in STEMI patients
after PCI treatment, improve cardiac function, reduce the incidence of MACE, and lower the risk of angina
pectoris and recurrent myocardial infarction.